India's new clinical trial rules establish an accelerated pathway for new drug approvals, but affordability remains… https://t.co/uhVXDZGLfr
Customer Logins
Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
Customer Logins
Our pricing and reimbursement research presented at ISPOR Europe
14 November 2018
Milena Izmirlieva
In research, presented at the ISPOR Europe meeting in Barcelona on 13 October, Associate Director Milena Izmirlieva examines the impact of securing marketing approval under an expedited pathway on pricing and reimbursement outcomes.
Related Posts
-
-
-
-
-
-
-
-
Explore
RELATED INDUSTRIES & TOPICS
Follow Us
Democrats explore creative ways to expand health insurance access with Medicare X https://t.co/kAsNBvtiuz
The creation of the Canadian Drug Agency and Pharmacare could mean big changes for drug prices https://t.co/8uMsHLXiAE
Norway’s Statistik Sentralbyrå (SSB) annual healthcare and pharmaceutical expenditure statistics confirms the accur… https://t.co/laLzZbrc79